Acrivon Q1 net loss $19.0M; cash $97.7M; key ACR-368 interim readout in H2 2026

Acrivon Therapeutics, Inc.

2026-Q1 EPS reported -$0.49

Net loss $19.0M vs $19.7M YoY; R&D $15.2M, G&A $4.7M.
Cash & equivalents $97.7M at March 31, 2026; plus $7.3M from equity financing, runway into Q3 2027.
ACR-368 Phase 2b registrational study: prespecified interim analysis of serous EC arms planned in H2 2026.
ACR-2316 Phase 1/2 shows tolerability and durable activity in AP3-prioritized lung cancers; expansion phase ongoing.
CDK11 inhibitor program (ACR-6840) IND submission targeted for H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.